Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.

ABSTRACT:

Background

After early-line (first- and second-line) endocrine therapy, hormone-receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancers (mBCs) become resistant to endocrine therapy. Genetic alterations may underlie resistance to endocrine therapies. This study aims to investigate the circulating tumor DNA (ctDNA) alterations and the clinical implication in hormone-receptor-positive, HER2-negative metastatic breast cancer patients with multiline endocrine therapy failure.

Methods

This registered study (NCT05079074, ClinicalTrials.gov) enrolled 104 patients with hormone-receptor-positive, HER2-negative metastatic breast cancer who progressed after the early-line endocrine therapy. ctDNA alterations were analyzed by next gen

SUBMITTER: Tang Y 

PROVIDER: S-EPMC9742482 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature